Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 28, 2017
Pharmacy Choice - News - Generic Drugs - July 28, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

6/28/17 - Apobiologix Applauds Supreme Court Decision in Sandoz Biosimilar Case
By a News Reporter-Staff News Editor at Biotech Week Apobiologix, a division of the Apotex Group focused on biologics innovation, announced their support of the Supreme Court decision in the Sandoz v Amgen case. Based on the new ruling, this notice may now be given prior to FDA approval. Earlier interpretations of BPCIA required that the 180- day
6/28/17 - Celltrion Healthcare Discuss Biosimilar Drug Approval and Look Ahead Into the Patent Expiry of Top Selling Biologics
SMi Reports: Celltrion Healthcare Present Proven Case Study Insight at 8th Annual Biosimilars Industry Summit
6/28/17 - FDA Announces Action Plan to Lower Cost of Prescription Drugs that Mirrors Senators Cotton, Collins, McCaskill, and Franken Bipartisan Bill
Washington, D.C.- U. S. Senators Susan Collins of Maine, Claire McCaskill of Missouri, Tom Cotton of Arkansas, and Al Franken of Minnesota today applauded the Food and Drug Administration's announcement that it will expedite the review of generic drug applications where competition is limited, a plan that mirrors one that the Senators have proposed
6/28/17 - Findings from A.Y.T. Wong et al Update Understanding of Biologics (Biosimilars in the United States: Emerging Issues in Litigation)
According to news reporting out of Hong Kong, People's Republic of China, by NewsRx editors, research stated, "Many first-generation biologics will lose their patent protection by 2020. For more information on this research see: Biosimilars in the United States: Emerging Issues in Litigation. Biodrugs, 2017; 31: 189-205. Biodrugs can be contacted a
6/28/17 - Food and Drug Administration Announces Action Plan that Mirrors Collins, McCaskill, Cotton, Franken Bipartisan Bill to Lower Cost of Prescription...
Washington, D.C.- U.S. Senators Susan Collins, Claire McCaskill, Tom Cotton, and Al Franken today applauded the Food and Drug Administration's announcement that it will expedite the review of generic drug applications where competition is limited, a plan that mirrors one that the Senators have proposed in their bipartisan bill, the Making Pharmaceu
6/28/17 - GLENMARK GETS US NOD FOR GENERIC INFLAMMATORY DRUG
Glenmark Pharmaceuticals has secured the approval of the US Food and Drug Administration for its generic version of anti-inflammatory drug.
6/28/17 - Global Adalimumab Biosimilar Market 2016
DecisionDatabases.com announces a new report Global Adalimumab Biosimilar Industry 2016 Market Research Report added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the ...
6/28/17 - Investigators at Amgen Report Findings in Biotherapies and Biologicals (Developing the Totality of Evidence for Biosimilars: Regulatory...
Investigators at Amgen Report Findings in Biotherapies and Biologicals. By a News Reporter-Staff News Editor at Biotech Week Current study results on Drugs and Therapies- Biotherapies and Biologicals have been published. According to news originating from Thousand Oaks, California, by NewsRx correspondents, research stated, "Biosimilars are highl
6/28/17 - NATCO TO SELL GENERIC CANCER DRUG IN US
Natco Pharma has obtained final approval from the US Food and Drug administration for its Abbreviated New Drug Application for the generic version of Vidaza. Natco Pharma and its marketing partner Breckenridge Pharmaceutical Inc were planning to launch Azacitidine in the US market. Celgene Corporation's Vidaza is a prescription anti- cancer drug...
6/28/17 - New Biologics Data Have Been Reported by Investigators at Pfizer (Can biosimilars help achieve the goals of US health care reform?)
By a News Reporter-Staff News Editor at Biotech Week Data detailed on Biotechnology- Biologics have been presented. According to news reporting from New York City, New York, by NewsRx journalists, research stated, "The US Patient Protection and Affordable Care Act aims to expand health care coverage, contain costs, and improve health care quality
6/28/17 - New Findings from E.D. Deeks et al Broadens Understanding of Rheumatoid Arthritis [CT-P10 (Truxima ?): A Rituximab Biosimilar]
According to news reporting originating in Auckland, New Zealand, by NewsRx editors, the research stated, "CT-P10 is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab. For more information on this research see: CT-P10: A Rituximab Biosimilar. Biodrugs, 2017; 31: 275-278. Biodrugs can be contacted at: Adis Int Ltd, 5 The
6/28/17 - Sen. Grassley Supports FDA Steps to Improve Access to Less Costly Medications
Charles E. Grassley, R- Iowa, Senate Judiciary Committee chairman, issued the following statement in support for the Food and Drug Administration Commissioner's actions to help expand access to lower-cost prescription medications through improved transparency and reduced red tape:. Just last week, I urged the FDA to examine legislation aimed at red
6/27/17 - Biosimilar Drug Market Research Report: United States Analysis 2017-2022
The Report added on USBiosimilar Drug Marketadded by DecisionDatabases.com to its huge database. This research study is segmented on the bases of applications, technology, geography and types. The Report provides a detailed Biosim...
6/27/17 - European Markets Pulled Back As Euro Strengthens
Several factors weighed on investor sentiment Tuesday, including a profit warning from UK retailer Debenhams and the failed takeover of German drug-maker Stada. The Euro also strengthened against the dollar after some comments from European Central Bank President Mario Draghi. The European Central Bank will need to be prudent in withdrawing monetar
6/27/17 - FDA Tackles Drug Competition to Improve Patient Access
To encourage generic drug development, the FDA posted a list of branded drugs that have no listed patents or exclusivities and for which the agency has yet to approve a generic drug application. The FDA will continue to refine and update the list periodically to ensure continued transparency around drug categories where increased competition has th
6/27/17 - FDA takes steps to boost generic competition, limit prices
The Food and Drug Administration said it's taking steps to boost the number of generic prescription drugs on the market in an effort to make medicines more affordable and to prevent price gouging. Scott Gottlieb made addressing prices a priority, saying that agency can help by increasing market competition. While the FDA reviews and approves medica
6/27/17 - GAO Issues Report on Generic Drug User Fees
What GAO Found: "Since the enactment of the Generic Drug User Fee Amendments of 2012, the Food and Drug Administration's reliance on user fees has increased from $121 million in fiscal year 2013 to $373 million in fiscal year 2016, or 45 percent of total program obligations in fiscal year 2013 to 76 percent in fiscal year 2016. FDA carried over $17
6/27/17 - Glenmark receives ANDA approval for Indomethacin Extended-Release Capsules [India Infoline News Service]
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Indomethacin Extended Release Capsules. Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Indomethacin Extended Release Capsules USP, 75 mg, the generic versi
6/27/17 - Global Gastrointestinal Drugs Market: Emergence of Biosimilars to be a Trend Gaining Traction, says TMR
These three players are: Valeant Pharmaceuticals Inc., Janssen Biotech Inc., and Takeda Pharmaceutical. Some of the other players in the market are: Bayer AG, Boehringer Ingelheim GmbH Sanofi, Allergan Plc, AstraZeneca, GlaxoSmithKline, Allergan Plc., and Abbott Laboratories. Favorable reimbursement policies, and increasing geriatric population, wh
6/27/17 - Grassley Supports FDA Steps to Improve Access to Less Costly Medications
WASHINGTON- Senate Judiciary Committee Chairman Chuck Grassley today expressed support for the Food and Drug Administration Commissioner's actions to help expand access to lower-cost prescription medications through improved transparency and reduced red tape. Just last week, I urged the FDA to examine legislation aimed at reducing anti-competitive.
6/27/17 - Horizon Pharma plc Announces District Court Decision to Uphold VIMOVO (naproxen/esomeprazole magnesium) Patents
Horizon Pharma plc, a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the United States District Court for the District of New Jersey upheld the validity of two Horizon Pharma pa
6/27/17 - Natco Pharma receives USFDA's final approval for generic azacitidine [India Infoline News Service]
Natco Pharma on Tuesday has received final approval of Abbreviated New Drug Application from the US Food and Drug Administration for Azacitidine for Injection. Natco Pharma on Tuesday has received final approval of Abbreviated New Drug Application from the US Food and Drug Administration for Azacitidine for Injection, 100 mg per vial, single-dose v
6/27/17 - Slayback Pharma Appoints Patrick McIntosh as Head of Commercial Operations
Slayback Pharma, LLC, a privately held pharmaceutical research and development company, announced today the appointment of Patrick McIntosh as Senior Vice President and Head of Commercial Operations. Patrick McIntosh joins Slayback with more than 25 years of commercial experience in the pharmaceutical sector, including prior roles at Renaissance, T
6/26/17 - AAM Biosimilars Council Praises Unanimous Supreme Court Ruling That Will Accelerate Patient Access to Biosimilar Medicines
By a News Reporter-Staff News Editor at Pharma Business Week The Association for Accessible Medicines applauded the U.S. Supreme Court's decision this week in Sandoz Inc. v. The Biosimilars Council, a division of the AAM, filed an amicus brief in the case consistent with the Court's ruling, recognizing delaying competition would cost patients, in
6/26/17 - Breckenridge Pharmaceutical, Inc. Announces Final ANDA Approval for Azacitidine for Injection (Vidaza)
Breckenridge Pharmaceutical, Inc. announced that FDA has granted final approval of its ANDA Azacitidine for Injection, 100 mg per vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation. Breckenridge submitted the ANDA with its development and manufacturing partner Natco Pharma Limited. About Breckenridge: Breckenridge...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415